Sign Out
Posology: The dose of linagliptin is 5 mg once daily. When linagliptin is added to metformin, the dose of metformin should be maintained, and linagliptin administered concomitantly.
When linagliptin is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin, may be considered to reduce the risk of hypoglycaemia (see Precautions).
Special populations: Renal impairment: For patients with renal impairment, no dose adjustment for Trajenta is required.
Hepatic impairment: Pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment but clinical experience in such patients is lacking.
Elderly: No dose adjustment is necessary based on age.
Paediatric population: A clinical trial did not establish efficacy in paediatric patients 10 to 17 years of age (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions). Therefore, treatment of children and adolescents with Trajenta is not recommended. Trajenta has not been studied in paediatric patients under 10 years of age.
Method of administration: Trajenta can be taken with or without a meal at any time of the day. If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.
